选择语言

SOST

SOST信息

英文名称:Sclerostin上市药物数量1
中文名称硬骨素临床药物数量5
靶点别称Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD最高研发阶段批准上市
英文名称:Sclerostin
中文名称硬骨素
靶点别称Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
上市药物数量1
临床药物数量5
最高研发阶段Approved

SOST产品列表

  • 属性

    Protein (2)

  • 产品库

    在线 (2)

  • 物种

    Human (2)

  • 标签

    His Tag (2)

  • 标记

    Biotin-labeled (1)Unconjugated (1)

共 2 项数据
  • 1

SOST分子背景

Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

SOST分子别名

SOST,VBCH

产品评论

  • 分子信息
  • 产品列表